157 related articles for article (PubMed ID: 2974027)
1. Different expression of CD3 and CD22 in leukemic cells according to whether tested in suspension or fixed on slides.
Rani S; De Oliveira MS; Catovsky D
Hematol Pathol; 1988; 2(2):73-8. PubMed ID: 2974027
[TBL] [Abstract][Full Text] [Related]
2. Detection of intracellular lymphoid differentiation antigens by flow cytometry in acute lymphoblastic leukemia.
Sartor M; Bradstock K
Cytometry; 1994 Sep; 18(3):119-22. PubMed ID: 7813331
[TBL] [Abstract][Full Text] [Related]
3. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases.
Janossy G; Coustan-Smith E; Campana D
Leukemia; 1989 Mar; 3(3):170-81. PubMed ID: 2465463
[TBL] [Abstract][Full Text] [Related]
4. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
5. Human hematopoietic cell lines: a model system for study of minimal residual disease detection technique in acute leukemia.
Koníková E; Kusenda J; Babusíková O; Glasová M
Neoplasma; 1995; 42(5):227-34. PubMed ID: 8552200
[TBL] [Abstract][Full Text] [Related]
6. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis.
Knapp W; Strobl H; Majdic O
Cytometry; 1994 Dec; 18(4):187-98. PubMed ID: 7534675
[TBL] [Abstract][Full Text] [Related]
10. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
11. Acute kidney graft rejection. A morphological and immunohistological study on "zero-hour" and follow-up biopsies with special emphasis on cellular infiltrates and adhesion molecules.
Andersen CB; Ladefoged SD; Larsen S
APMIS; 1994 Jan; 102(1):23-37. PubMed ID: 7513171
[TBL] [Abstract][Full Text] [Related]
12. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous expression of CD13, CD22 and CD25 is related to the expression of Fc epsilon R1 in non-lymphoid leukemia.
Sato N; Kishi K; Toba K; Watanabe K; Itoh H; Narita M; Takahashi M; Aizawa Y
Leuk Res; 2004 Jul; 28(7):691-8. PubMed ID: 15158090
[TBL] [Abstract][Full Text] [Related]
14. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
15. CD22 as a target of passive immunotherapy.
Cesano A; Gayko U
Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
[TBL] [Abstract][Full Text] [Related]
16. Concomitant delineation of surface Ig, B-cell differentiation antigens, and HLADR on lymphoid proliferations using three-color immunocytometry.
Segal GH; Edinger MG; Owen M; McNealis M; Lopez P; Perkins A; Linden MD; Fishleder AJ; Stoler MH; Tubbs RR
Cytometry; 1991; 12(4):350-9. PubMed ID: 1712263
[TBL] [Abstract][Full Text] [Related]
17. Methods in pathology. Identification of T-cell lymphomas in paraffin-embedded tissues using polyclonal anti-CD3 antibody: comparison with frozen section immunophenotyping and genotypic analysis.
Anderson C; Rezuke WN; Kosciol CM; Pastuszak WT; Cartun RW
Mod Pathol; 1991 May; 4(3):358-62. PubMed ID: 1829834
[TBL] [Abstract][Full Text] [Related]
18. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.
Engel P; Nojima Y; Rothstein D; Zhou LJ; Wilson GL; Kehrl JH; Tedder TF
J Immunol; 1993 Jun; 150(11):4719-32. PubMed ID: 7684411
[TBL] [Abstract][Full Text] [Related]
19. Myeloid lineage involvement in acute lymphoblastic leukemia: a morphology antibody chromosomes (MAC) study.
Larramendy M; el-Rifai W; Saarinen U; Alitalo R; Luomahaara S; Knuutila S
Exp Hematol; 1995 Dec; 23(14):1563-7. PubMed ID: 8542947
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.
Belov L; de la Vega O; dos Remedios CG; Mulligan SP; Christopherson RI
Cancer Res; 2001 Jun; 61(11):4483-9. PubMed ID: 11389079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
